Abstract: Herbicidal compositions comprising (a) bentazon-sodium and (b) an ALS inhibitor and (c) an ACCase inhibitor controls susceptible and resistant weeds in crops, e.g., rice, wheat, barley, oats, rye, sorghum, corn/maize, pastures, grasslands, rangelands, fallowland, turf, tree and vine orchards and IVM, but also additionally in ALS and ACC'ase tolerant crops.

Abstract: The present invention relates to a heat-generating composition, comprising a hetero-structure nanomaterial which comprises (a) a first material comprising at least one component selected from the group consisting of a metal, a metal chalcogen, a metal pnicogen, an alloy and a multi-component hybrid structure thereof; and (b) a second material comprising at least one component selected from the group consisting of metal, metal chalcogen, metal pnicogen, alloy and the multi-component hybrid structure thereof; wherein the first material is enclosed in the second material; wherein at least one of the first material and the second material comprise a magnetic material. The specific loss power of the present nanomaterial is much higher than that of conventional nanomaterials (e.g., 40-fold higher than commercially accessible Feridex) and may be controlled by changing compositions or ratios of the first material and/or the second material.

Abstract: An array of pharmaceutical formulations characterized by the presence of molecular oxygen comprising four elements which, in combination, furnish benefits for the health of patients with HIV AIDS: (i) weight increase of the patient; (ii) increase of appetite; (iii) reduction of diarrhea; (iv) reduction of the wasting syndrome; (v) increase of stability of mood; (vi) increase of muscular mass. (vii) decrease of opportunistic diseases, in particular infections caused by Candida, herpes virus, cytomegalovirus, Kaposi's sarcoma; (viii) prolongation of the period wherein the patient does not require to take antiretrovirals; (ix) increase of acceptance of pharmacological treatment; x. reduction of gastritis, nausea or vomiting, headache; (xi) reduction of cases with anemia or thrombocytopenia; and (xii) a change in the phase of the disease in the patient.

Abstract: Compositions comprising undecylenic acid or citric acid and certain esters are effective for reducing malodors. The esters are in the molecular weight range of between 150-200 when the acid is undecylenic acid and in the range of between 130-230 when the acid is citric acid. These compositions can be used in perfumed products, household products and personal care products.

Abstract: The present invention relates to targeted drug delivery of a drug or therapeutic agent through medical devices coated with formulations comprising of therapeutic agent. The coating on medical devices comprises of therapeutic agent(s), affinity vehicle(s) and additives for targeted drug delivery of biologically active material(s). The invention provides a method of manufacturing the formulation, method of coating the medical devices with such formulations to achieve controlled delivery of optimum drug dose at the target site within the body, desirable drug retention on the medical devices in vivo and in vitro and desirable drug release at the target tissue in-vivo. The invention this provides a mechanism to enhance the bioavailability of the therapeutic agent at the target tissue in the treatment of restenosis thereby reduces the actual dose of the therapeutic agent and provides a very thin layer of coating on the surface of the medical device.

Abstract: A stabilized composition comprising at least one adrenergic compound and at least one antioxidant selected from the group consisting of a bisulfate, a metabisulfite and a sulfite compound.

Abstract: A biocompatible film includes a single layer having a plurality of components, at least one of the plurality of components having a predetermined non-uniform distribution in the thickness direction of the single layer. The at least one of the plurality of components that has a non-uniform distribution in the thickness direction of the single layer may have a substantially uniform distribution in the longitudinal and lateral directions of the single layer. The biocompatible film can be made by depositing a fluid composition including a film forming material and at least one other component immiscible with the film forming material and having a density different than the film forming material into a single layer, and drying the single layer such that the at least one other component has a predetermined non-uniform distribution in the thickness direction of the single layer after drying.

Abstract: An anti-hypothermia composition is provided, in particular an anti-hypothermia composition that prevents hypothermia caused by general anesthesia during surgical operations. The composition prevents hypothermia by preventing the decrease in the biological function of patients and correcting acidosis. Specifically, the anti-hypothermia composition is a preparation containing a bicarbonate ion and provided in the form of an infusion fluid. The infusion fluid preferably contains sodium bicarbonate as a major component that serves as a source of the bicarbonate ion, along with each or a combination of other electrolytes, glucose and amino acids.

Abstract: A composition for a broad-spectrum antiviral agent with excellent preservation stability, which comprises a pure chlorine dioxide solution comprising a chlorine dioxide gas dissolved therein, a chlorite, and a pH adjuster.

Abstract: Extended release pharmaceutical compositions of levetiracetam or pharmaceutically acceptable salts thereof in the form of a tablet comprising glyceryl behenate and a polymethacrylate polymer with at least one pharmaceutically acceptable excipient.

Abstract: A process for preparing an aqueous concentrate glyphosate salt composition comprises (i) neutralizing glyphosate acid with potassium hydroxide and a minor amount of a low molecular weight organic amine in presence of water to produce a glyphosate salt solution having a pH of about 4.8 to about 5.0, where the neutralizing operation comprises a first neutralization step in which a slurry or glyphosate salt solution having a pH of about 4.4 to about 4.7 is produced and a second neutralization step in which the pH is adjusted to about 4.8 to about 5.0; and (ii) after the first neutralization step and before, during or after the second neutralization step, adding further water if necessary and optionally at least one surfactant to produce a final composition having a total glyphosate a.e. concentration not less than about 360 g/l.

Abstract: This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, as a combined composition for simultaneous, separate or sequential use for treating ischemia. The present invention also relates to the use of at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, for the preparation of a combined pharmaceutical composition for treating ischemia.

Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.

Abstract: There are provided a chlorine dioxide solution composition whose solute includes dissolved chlorine dioxide and chlorite; and a solution composition encapsulating body including a glass vessel or enameled vessel and the chlorine dioxide solution composition hermetically sealed therein.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.

Abstract: A method for preparing a concentrated solution containing water, citrate ions and silver ions, including providing an amount of trisilver citrate, providing an amount of citric acid, wherein the amount of the citric acid is at least 19 times the amount of the trisilver citrate by weight, and mixing the trisilver citrate and the citric acid in an amount of water to produce the concentrated solution, wherein the amount of water is selected so that the concentrated solution has a citrate ion concentration which is at least 300 grams per liter. A concentrated solution containing water, citrate ions and silver ions, wherein the concentrated solution has a silver ion concentration which is at least 10 grams per liter. A diluted solution prepared by adding water to a concentrated solution containing water, citrate ions and silver ions.

Abstract: The invention relates to a composition in the form of an emulsion that can be expanded by an aerosol dispenser, characterized in that it comprises from 15 to 20 volume % of alcohol, from 1 to 10 volume % of C3-C8 polyolen, a thickening agent, at least one non-ionic surfactant, a wetting agent, and one or more active ingredients dissolved or in suspension; the invention also relates to the medical and cosmetic applications thereof.

Abstract: Composition of a Dead Sea extract and at least one plant extract of a Himalayan origin are provided for topical applications.

Abstract: A transdermal analgesic applicator configured to provide a visual signal subsequent sufficient absorption of an analgesic compound ensuing the transdermal analgesic applicator being applied to the skin of a patient. The transdermal analgesic applicator includes a first layer that is impermeable and has integrally formed therewith on at least a portion thereof a plurality of microcapsules containing a thermochromic dye mixture. The first layer having the portion of microcapsules presents a first color at ambient room temperature and a second color at temperature greater than the first temperature as a result of being placed on the skin of a patient. A second layer containing an analgesic compound is secured to the first layer. The first layer changes from the first color to the second color subsequent the first layer changing from the first temperature to the second temperature, which the rate of temperature change is approximately equivalent to the absorption rate of the analgesic compound.